Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

New Evidence That Vinegar May Be Natural Fat-fighter
Researchers in Japan are reporting new evidence that the ordinary vinegar - a staple in oil-and-vinegar salad dressings, pickles, and other foods - may live up to its age-old reputation in folk medicine as a health promoter. They are reporting new evidence that vinegar can help prevent accumulation of body fat and weight gain. Their study is scheduled for the July 8 issue of ACS" Journal of Agricultural and Food Chemistry, a bi-weekly publication.
generic viagra online
What Is Bell's Palsy? What Causes Bell's Palsy?
Bell"s palsy is either weakness or paralysis of the muscles on one side of the face due to malfunction of the facial nerve. It usually starts suddenly - somebody can wake up in the morning and find that one side of the face does not move. Sometimes one eyelid may be affected, meaning that the patient is unable to blink properly from one eye.
News of the day
Advances In Stem Cell Research: New Interdisciplinary Volume
In a variety of organisms, from zebrafish to fruit flies to humans, stem cells have the potential to differentiate into a variety of tissues--and, in some cases, to give rise to a complete new organism. Stem cell research, therefore, has attracted the attention of a range of biologists--reproductive biologists, cancer biologists, cell and developmental biologists, and others--who have all recognized its importance and therapeutic potential.
Medical Devices

UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323

UCB and Biogen Idec announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted. CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis. For UCB, results of this interim analysis trigger a re-valuation of the intangible asset "CDP323". UCB expects a non-cash, non-recurring impairment of a high double-digit million pre-tax euro amount. This will be more than compensated by cash, non-recurring capital gains, which resulted from the divestitures UCB made earlier this year. More information on the financial impacts of both the impairment and the capital gains will be included in the Half Year Report 2009 of UCB, due July 31, 2009. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects an estimated 1.1 - 2.5 million people worldwide. Although the exact cause is unknown, MS occurs as a result of loss of the protective outer coating on nerves in the brain and spinal cord. Deterioration in the way that messages are transmitted around the body leads to loss of movement and other body functions. Symptoms of MS can include vision problems, loss of balance, numbness, difficulty walking and paralysis. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec"s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009